Atlas Trials

The Relapse from MRD Negativity As Indication for Treatment (REMNANT) Study

Clinical trial NCT04513639 · RECRUITING

Trial details

NCT number
NCT04513639
Sponsor
Oslo University Hospital
Status
RECRUITING
Phase
Phase 2, Phase 3
Study type
INTERVENTIONAL
Multiple Myeloma
Start date
2020-08-27
Primary completion
2031-06-01
Enrollment
176

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.